Stray Dog

Hims & Hers Q1 2026 Earnings: Short-Term Pain, Long-Term Gain

Key takeaways

  1. Revenue rose only 4%, to $608 million, as Hims stopped promoting its own copies of weight-loss drugs and switched to branded Wegovy.
  2. Most of the $92 million net loss was charges management called one-time or non-cash; day-to-day operations still generated $89 million in cash.
  3. Branded Wegovy is ramping fast, with over 125,000 shipments in six weeks, though retention beyond the first month was not disclosed.
  4. Monthly shipping stacks up revenue, so management expects faster growth in the second half and raised full-year guidance to $2.8 to $3.0 billion.
  5. The video calls it short-term pain for long-term gain: the subscribers are the asset, and their data is the moat.

Ask a question